RZ 001
Alternative Names: RZ-001Latest Information Update: 13 Aug 2024
At a glance
- Originator Rznomics
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glioblastoma; Liver cancer
Most Recent Events
- 13 Aug 2024 Phase-I clinical trials in Liver cancer (Combination therapy) in South Korea (Intratumoural) (Rznomics pipeline; August 2024)
- 05 Aug 2024 Ministry of Food and Drug Safety (MFDS) approves IND application for RZ 001 in Liver cancer (Combination therapy)
- 01 Aug 2024 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Late-stage disease) in South Korea (Intratumoural) (NCT06102525)